832 results about "Vascular Disorder" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.

The invention relates to the technical field of health monitoring, in particular to a cardiovascular disease data fusion and multi-dimensional health assessment method, which comprises the following steps of: acquiring multi-source data of a patient through a sensor and wearable equipment, preprocessing the acquired data, ensuring data integrity, extracting physiological features by adopting a convolutional neural network, and evaluating the health of the patient. The method comprises the steps of extracting non-physiological data features through principal component analysis, constructing a multi-dimensional feature set, identifying cardiovascular disease related risk factors through a random forest algorithm, distributing weights through a logistic regression algorithm to generate individualized risk scores, analyzing time sequence trends of the risk factors based on a long and short-term memory network model, and generating dynamic risk scores in real time. When the score exceeds a preset threshold value, an early warning mechanism is automatically triggered, and a patient and medical staff are notified through an application program; according to the method, accurate assessment and personalized intervention of cardiovascular health are realized through multi-source data fusion and dynamic analysis, and the method has high efficiency and timeliness.

The invention relates to the technical field of cardiovascular disease treatment, and discloses a cardiovascular disease medical decision support method based on a large model, and the method comprises the steps: obtaining multi-modal cardiovascular disease medical data, constructing a multi-source heterogeneous data set, carrying out the preprocessing and feature fusion, and constructing a combined representation model based on the pre-training large model and the fusion of traditional and western medicine knowledge. And designing a hierarchical space-time diagram convolutional network to generate a dynamic physiological state code of the patient, and constructing a multi-target optimization decision tree to generate a treatment scheme containing western medicines, traditional Chinese medicine prescriptions and non-drug intervention. A federal learning framework is adopted to cooperatively train a local model, data security is guaranteed, a global model is optimized, and a curative effect attribution module is further arranged to correct decision deviation. According to the method, multi-modal data and traditional Chinese and western medicine knowledge are integrated, personalized treatment scheme generation is achieved, data safety is guaranteed, and the cardiovascular disease diagnosis and treatment level is improved.

The systems, devices, and methods presented herein use a blood pump to obtain measurements of cardiac function. The system can quantify the functioning of the native heart by measuring certain parameters / signals such as aortic pressure or motor current, then calculate and display one or more cardiac parameters and heart function parameters, such as left ventricular pressure, left ventricular end diastolic pressure, or cardiac power output. These parameters provide valuable information to a user regarding current cardiac function, as well as positioning and function of the blood pump. In some embodiments, the system can act as a diagnostic and therapeutic tool. Providing cardiac parameters in real-time, along with warnings about adverse effects and recommendations to support cardiac function, such as increasing or decreasing the volumetric flow rate of blood pumped by the device, administering pharmaceutical therapies, and / or repositioning the blood pump allow clinicians to better support and treat cardiovascular disease.

The present invention provides a compound as shown in formula (I), and a pharmaceutically acceptable salt of the compound. The compound in the present invention exhibits a strong inhibitory effect on Lp(a) assembly, and can be used for treating cardiovascular diseases (CVD).

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

The invention relates to the technical field of health status assessment, in particular to a cardiovascular disease layered early warning system, which is characterized in that blood vessel compliance and pulse wave velocity are extracted, arterial dilation capacity is measured, blood vessel elasticity is calculated, blood perfusion distribution is detected, and abnormal vasoconstriction is classified on the basis of a hemodynamic state and a heart electrical activity state; in combination with the thickness of the blood vessel wall and the blood vessel stenosis rate, the plaque deposition condition is analyzed, the arteriosclerosis score is calculated, the thrombosis tendency is detected, the local blood flow blocking degree is quantified, the isolation forest algorithm is adopted, the blood flow dynamic change is calculated, the heart rhythm abnormality is analyzed, the acute vascular occlusion probability is measured, and the sudden heart rhythm abnormality risk is evaluated. And based on a gradient boosting tree algorithm, screening high-risk cases, matching medical intervention measures, setting a risk buffer mechanism, adjusting an individual health management strategy, and optimizing a cardiovascular risk hierarchical early warning system.

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

The invention relates to a cardiovascular disease risk prediction system, which comprises a user terminal module, an edge computing module, a cloud intelligent module, an application service module and a system support module, wherein the user terminal module comprises an intelligent sensing equipment cluster unit and a mobile terminal data entry unit; and the intelligent sensing equipment cluster unit adopts a millimeter wave radar-PPG fusion sensor, monitors subcutaneous 0.5 mm depth arterial vibration through a 60GHz radar array, is aligned with a photoplethysmogram signal in a space-time manner, and performs user data acquisition based on a surface plasma resonance chip. According to the cardiovascular disease risk prediction method and system, real-time signal processing is realized by adopting JetsonAGX through a heterogeneous calculation architecture, medical image accelerated calculation is performed by using NVIDIAClara, non-out-of-domain joint modeling of data of hospitals is supported through federal learning, privacy protection reasoning based on homomorphic encryption is realized, and full-process closed-loop management is realized by adopting a layered modular architecture. And the accuracy of cardiovascular disease risk prediction is improved.

The invention discloses a myocardial infarction patient risk assessment model construction method and system, and particularly relates to the field of cardiovascular disease prediction, and the method comprises the following steps: I, collecting modal data of a hospital information system, an image filing system and wearable equipment, and integrating the modal data; according to the method, the accuracy of myocardial infarction risk prediction can be optimized, risk assessment not only depends on statistical characteristics, but also fuses pathophysiological mechanisms, the clinical interpretability of prediction is improved, the limitation that a traditional data-driven method is only based on correlation modeling is avoided, the optimal treatment scheme can be dynamically adjusted, data-driven personalized medical treatment is achieved, and the risk assessment efficiency is improved. The scientificity of intervention decision making is improved; the method can quickly adapt to new patient data, improve the individualized prediction ability, improve the data utilization rate, enhance the generalization ability of the model for different patient groups, avoid training the whole model from zero, greatly reduce the consumption of computing resources, make up for the problem of insufficient data of a single patient, and improve the prediction ability of rare cases.

The invention relates to lauroyl cilostazol as well as a preparation method and application thereof. Wherein the lauroyl cilostazol is sterile, and preferably, the lauroyl cilostazol is a crystal. The invention further provides application of the lauroyl cilostazol in preparing medicines for treating cerebral infarction, cerebrovascular diseases, atherosclerosis, diabetic complications, peripheral vascular diseases, Reynolds diseases, intermittent claudication, ischemic heart diseases and acute coronary syndromes. The lauroyl cilostazol has the remarkable long-acting characteristic.

According to the precise diagnosis and treatment integrated platform and method based on the coupling model, the cavitation effect is predicted through numerical simulation, negative feedback adjustment is conducted on microbubble mediated ultrasonic treatment, and precise control over the microbubble mediated ultrasonic treatment is achieved. Acoustic parameters are adjusted in real time, it can be ensured that treatment focuses on a lesion area, damage to surrounding healthy tissue is reduced, and therefore the accuracy and safety of treatment are improved. The platform integrates cavitation detection and an acoustic feedback mechanism, the microbubble cavitation effect can be monitored in real time, and treatment parameters can be automatically adjusted. Negative feedback closed-loop control can ensure a stable cavitation state, tissue damage caused by excessive cavitation is effectively avoided, and the stability and reliability of treatment are improved. The platform simplifies the operation process of controlling acoustic parameters. A doctor can complete the whole process from treatment to monitoring on the same operation interface through the integrated platform, and convenience and efficiency of clinical operation are improved. The platform is not only suitable for tumor treatment, ablation and drug delivery, but also can be applied to multiple treatment fields such as vascular diseases and neuromodulation, and has wide clinical application prospects and market potential.

The invention relates to the technical field of cellular immunotherapy, in particular to application of efonidipine in preparation of a dendritic cell immunologic adjuvant. The invention provides an application of efonidipine in preparation of a dendritic cell immunologic adjuvant. It is found that efonidipine can promote maturation, migration and antigen presentation functions of DCs, and the homing ability of DCs and CD8 + T cell activation are remarkably improved. The activation aspect of efonidipine on DCs comprises improvement of expression of maturation indexes CD80, CD40 and CD86, expression of a migration index CCR7, activation of CD8 + T cells by antigen presentation and the like. The efonidipine used in the invention is a drug approved by FDA for clinical treatment of cardiovascular diseases, the application of the efonidipine in immunotherapy is found, new use of old drugs is realized, and the efonidipine has great economic value.

The invention provides an echocardiogram video abstraction method based on a hierarchical space-time attention mechanism, and the method comprises the steps: obtaining an echocardiogram, inputting the echocardiogram into an anatomy and physiological basic model of a key frame recognition task, and obtaining key frame information; inputting the key frame information into a multi-dimensional spatial-temporal feature extraction model to obtain feature information and frequency domain information; fusing the feature information and the frequency domain information; performing key frame enhancement processing on the fusion information by adopting an SE channel attention mechanism to obtain key frame anatomical feature expression; processing the key frame anatomical feature expression by adopting a key frame backtracking strategy and a classification network to obtain a key frame identification classification result; performing left ventricle segmentation on the classified image by adopting an improved U-Net left ventricle region segmentation network; estimating the area and volume of the left ventricle based on a segmentation result; fusing the estimated left ventricular area and volume by adopting a hierarchical attention mechanism and a cross-layer information fusion strategy to obtain a ventricular volume result; according to the method, through abstract extraction of the key information of the ultrasonic cardiac video, the clinical practicability of intelligent screening and auxiliary diagnosis of cardiovascular diseases based on ultrasonic is improved.

The invention discloses a pulmonary vascular endothelial barrier injury model and a construction method and application thereof, and relates to the technical field of biologication.The construction method of the pulmonary vascular endothelial barrier injury model comprises the following steps that a healthy mouse is adaptively fed for one week and then anesthetized with a medicine, oncostatin M recombinant protein is pretreated and then instilled into the lung of the mouse through an airway, and then the mouse is subjected to tumor cell apoptosis; obtaining a pulmonary vascular endothelial barrier injury model; the invention further discloses a pulmonary vascular endothelial barrier injury model, application of the model in preparation of a pulmonary vascular disease research model and application of the model in preparation of drugs for treating pulmonary vascular diseases. According to the pulmonary vascular endothelial barrier injury model as well as the construction method and the application thereof provided by the invention, the oncostatin M protein is combined with an oncostatin M receptor type II on an endothelial cell to activate a downstream signal channel, so that the endothelial barrier is damaged, a clear target spot is provided for the endothelial barrier injury, and a pulmonary injury mechanism can be deeply discussed.

The present invention relates to a free base crystal form of a nitrogen-containing heterocyclic derivative, an acid salt and a crystal form thereof, a preparation method therefor, and a use thereof. In particular, the present invention relates to a free base crystal form of a compound represented by a general formula, an acid salt and a crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the salt or crystal form, and a use thereof as an inhibitor in the treatment of diseases such as cardiovascular disease and cerebrovascular disease.

The invention discloses a perfusion laser balloon catheter and a balloon catheter system, the perfusion laser balloon catheter is provided with a far end and a near end which are opposite to each other, and the perfusion laser balloon catheter comprises a guide wire and a balloon catheter, the inner tube is fixedly arranged on the periphery of the guide wire in a sleeving mode, the far end of the inner tube is blocked by the blocking piece, the inner tube is provided with a medicine channel, and a first outlet communicated with the medicine channel is formed in the far end of the inner tube; the optical fiber extends along the inner tube, and the far-end part of the inner tube is provided with a light-emitting section; the balloon body is located on the periphery of the inner tube, and the far end of the balloon body is connected with the outer wall of the inner tube in a sealed mode; the first outer tube is located on the periphery of the inner tube and communicated with the near-end side of the balloon body, and a radial gap between the first outer tube and the inner tube serves as a fluid channel for inflating the balloon body. According to the perfusion laser balloon catheter, medicine can be better released, the uniformity of light emission is guaranteed, and therefore the treatment effect on vascular diseases is improved.

The invention relates to the technical field of biological medicines, and provides a novel DELTP polypeptide and application thereof in improving cTnI cardiovascular medicines, and a novel polypeptide and application thereof in medicines for treating cardiovascular diseases. The polypeptide has a unique amino acid sequence and is composed of an amino acid sequence SEQ. NO: 1: Asp-Glu-Leu-Thr-Pro (DELTP), an amino acid sequence SEQ. NO: 2: Arg-His-Met-Ser-Tyr (RHMST) and the like, and the cardiovascular function is improved by adjusting the phosphorylation level of cardiac troponin I (cTnI).

The invention discloses a multi-mode cardiovascular disease detection method based on comprehensive view analysis, and relates to the problems that in the automatic diagnosis technology of cardiovascular diseases (CVD), CVD progress analysis is difficult, and diagnosis and prevention are difficult to achieve as early as possible. Although the current CVD automatic diagnosis technology based on deep learning achieves a certain progress, most of the technologies are limited to analysis of single-mode data, and the progress of CVD cannot be comprehensively predicted. In order to solve the problem, the invention provides a multi-mode cardiovascular disease detection method based on comprehensive view analysis. Experiments show that the method uses the blood vessel segmentation image to assist the retina fundus image to perform cross-view learning, and enhances the feature perception of the model on the retina blood vessel; two multi-modal data of a retina fundus image and a non-invasive clinical index are used as input, so that the deep understanding of the model on a CVD event is enhanced; a multi-order belief interactive fusion method is used for carrying out fusion and complementation on multi-modal features, and the accuracy and reliability of detection are improved. The method is applied to CVD detection.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention discloses a cardiovascular disease multi-parameter joint monitoring method and system, and relates to the technical field of data processing. Comprising the following steps: monitoring multiple physiological parameters related to cardiovascular health of a patient by using wearable equipment to obtain monitoring data; preprocessing the monitoring data to obtain preprocessed monitoring data; respectively extracting time domain features, frequency domain features, nonlinear features and other statistical features from the preprocessed monitoring data to obtain multi-modal features; based on the multi-modal features, in combination with self-supervised learning of deep learning, a graph neural network and time sequence analysis, performing relation modeling, and performing data enhancement by using an adversarial generative network to obtain enhanced processing features; training a model by using marked normal and abnormal data by using feature importance scores and a random forest; and classifying real-time monitoring data by using the trained model, identifying normal and abnormal states, and obtaining an abnormal monitoring result.

The invention provides an intelligent diagnosis and treatment method, system and equipment based on individualized blood pressure management, a computer readable storage medium and application thereof, and relates to the field of intelligent medical treatment. The method comprises the following steps: acquiring blood pressure, electroencephalogram signals, cerebral blood flow velocity and arterial blood pressure data of a subject; analyzing based on the electroencephalogram signal and cerebral blood flow velocity data of the subject to obtain a neurovascular coupling index; obtaining an individualized blood pressure range based on the nerve and blood vessel coupling index and the arterial blood pressure data of the subject; whether the blood pressure of the subject is within the individualized blood pressure range or not is judged, and when the blood pressure of the subject is not within the individualized blood pressure range, information prompt for blood pressure control is output. According to the method disclosed by the invention, the blood pressure management is guided by determining the individualized blood pressure range of the cardiovascular and cerebrovascular disease patient, valuable resources are provided for researchers and clinicians in the field of cardiovascular and cerebrovascular disease diagnosis and treatment, and the method has important scientific research significance and clinical value.

The invention relates to the field of cardiovascular disease monitoring and risk assessment, in particular to a cardiovascular disease risk assessment method which is characterized by comprising the following steps: acquiring dynamic physiological feature data of a user; acquiring static physiological feature data of the user; performing feature extraction on the dynamic physiological feature data, performing normalization processing on the dynamic physiological feature data and the static physiological feature data, and generating structured input data; and inputting the structured input data into the pre-trained prediction model, and generating a cardiovascular disease risk assessment report, so that portable, accurate and easy-to-operate cardiovascular disease monitoring can be realized, the diagnosis cost is reduced, the portability is improved, and personalized cardiovascular disease risk assessment is realized.

The present disclosure, in part, provide compounds of Formula (I) that are VPS34 inhibitors, compositions, and methods of use thereof, such as in methods of treating cancer, diabetes, inflammatory diseases, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections:

The invention relates to a cardiovascular disease risk assessment system and method. On the basis of fully considering the influence of dimension index information of kidney-related risk factors on the occurrence risk of cardiovascular diseases, heart and kidney metabolic indexes are integrated. And a mathematical model Fine-Gray is used for screening predictive factors by a step-by-step method. On the premise that traditional cardiovascular disease risk factors are reserved, in order to give consideration to the accuracy and easy generalization of risk assessment, prediction factors are simplified through strict calculation and derivation; the method is constructed based on a small amount of clinically ubiquitous detection index information such as age, sex, smoking or not, systolic pressure (SBP), fasting blood glucose (FBG), non-high density lipoprotein cholesterol (non-HDL-C) and estimated glomerular filtration rate (eGFR) as predictive factors. The method has the advantages of simplicity and convenience in operation, less required information and low professional requirement. Meanwhile, the risk of the outcome of various clinical cardiovascular diseases (including CVD, ASCVD and HF) can be evaluated at the same time, and the method can be suitable for various scenes such as primary medical care and clinical diagnosis and treatment.

The invention provides a multi-modal AI diagnosis and risk grading system, method and device suitable for vascular diseases, a medium and a program product, and provides an innovative method for cardiovascular diagnosis of old people by combining hemodynamics and structural indexes and utilizing a multi-modal deep learning framework. According to the method, the diagnosis accuracy is improved, and the prediction capability is enhanced through operable risk scoring. The method is unique in that double diagnosis of functions and structures is integrated, and compared with a traditional method focusing on single diagnosis, the method provides more comprehensive cardiovascular health assessment. Besides, the system has high applicability and expandability, can be integrated with clinical and wearable equipment, and realizes real-time monitoring and risk assessment. In the future, the system can further enlarge the diagnosis range by incorporating data such as biomarkers and the like, and shows good future adaptability.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

The invention relates to the technical field of molecular diagnosis, on one hand, the invention relates to a coronary artery microvascular disease (CMVD) related biomarker, and the biomarker comprises one or two of MW0107116 and MW0104774; on the other hand, the invention relates to application of the biomarker in preparation of a diagnostic product for detecting coronary artery microvascular diseases. Compared with a traditional circulating biomarker, the metabolite MW0107116 and MW0104774 serving as the biomarker for diagnosing the coronary artery microvascular disease has higher specificity, can be used for preparing a diagnostic product for detecting the coronary artery microvascular disease, is beneficial to simplifying the diagnosis of the coronary artery microvascular disease, and can be used for detecting the coronary artery microvascular disease. And the biomarker is detected by collecting a blood sample from the radial artery of a patient, so that invasive examination of coronary angiography for collecting blood from the coronary artery is avoided, and the biomarker is more friendly to the patient and has important clinical significance.

The invention relates to the technical field of biological medicine, in particular to application of ADAMTS13 to occlusive cardiovascular and cerebrovascular diseases. On one hand, the invention provides the biomarker ADAMTS13 for establishing the collateral circulation of the patient suffering from the occlusive cardiovascular and cerebrovascular diseases, and the biomarker ADAMTS13 can be used as a target spot for diagnosing, preventing and treating the occlusive cardiovascular and cerebrovascular diseases and can effectively predict the establishment of the collateral circulation of the patient suffering from the occlusive cardiovascular and cerebrovascular diseases and prevent the development of adverse cardiovascular events; the method has important value on clinical cardiovascular events, and can improve the survival rate of patients with occlusive vascular diseases and improve long-term prognosis; on the other hand, the invention provides an ADAMTS13 recombinant protein, the amino acid sequence of which is as shown in SEQ ID No: 1, and the ADAMTS13 recombinant protein can improve the proliferation, migration, invasion and tube forming capabilities of endothelial cells, and has important clinical application value for developing drugs for preventing and / or treating occlusive cardiovascular and cerebrovascular diseases.

The invention relates to the technical field of biological medicine, in particular to a novel polypeptide and application thereof in medicine for treating cardiovascular diseases. The polypeptide has a unique amino acid sequence, and is composed of an amino acid sequence of SEQ. NO: 1: Leu-Asn-Pro-Thr-Glu (LNPTG), an amino acid sequence of SEQ. NO: 2: Val-His-Met-Arg-Tyr (VHMRY), and the like. The polypeptide has a unique amino acid sequence, and provides a new way for the treatment of cardiovascular diseases by adjusting the activity of AMPK and improving the cardiovascular function.